according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

SECTION 1. IDENTIFICATION

Product name : Sitagliptin / Metformin Extended Release Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

Acute toxicity (Oral) : Category 4

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : If small particles are generated during further processing, han-

dling or by other means, may form combustible dust concentra-

tions in air.

H302 Harmful if swallowed.

Precautionary Statements : Prevention:

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel

unwell. Rinse mouth.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 09/28/2024 Date of first issue: 11/07/2014 11.2 29118-00025

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
metformin hydrochloride	1115-70-4	>= 50 - < 70
Cellulose	9004-34-6	>= 10 - < 20
Sitagliptin	654671-77-9	>= 5 - < 10
Kaolin	1332-58-7	>= 1 - < 5
Titanium dioxide	13463-67-7	>= 0.1 - < 1

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact Wash with water and soap.

Get medical attention if symptoms occur.

In case of eye contact If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting unless directed to do If swallowed

> so by medical personnel. Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

Most important symptoms

Harmful if swallowed.

and effects, both acute and

Protection of first-aiders

Contact with dust can cause mechanical irritation or drying of

the skin.

delaved

Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing None known.

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

media

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Metal oxides

Nitrogen oxides (NOx)

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation

Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage

Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid

Do not store with the following product types:

Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

inert or nuisance dust 50 Million particles per cubic foot

Value type (Form of exposure): TWA (total dust)

Basis: OSHA Z-3

15 mg/m³

Value type (Form of exposure): TWA (total dust)

Basis: OSHA Z-3

5 mg/m³

Value type (Form of exposure): TWA (respirable fraction)

Basis: OSHA Z-3

15 Million particles per cubic foot

Value type (Form of exposure): TWA (respirable fraction)

Basis: OSHA Z-3

Dust, nuisance dust and par-

ticulates

10 mg/m³

Value type (Form of exposure): PEL (Total dust)

Basis: CAL PEL

5 mg/m³

Value type (Form of exposure): PEL (respirable dust fraction)

Basis: CAL PEL

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
metformin hydrochloride	1115-70-4	TWA	1 mg/m3 (OEB 1)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m³	OSHA Z-1
Sitagliptin	654671-77-9	TWA	0.5 mg/m3 (OEB 2)	Internal
Kaolin	1332-58-7	TWA (Respirable particulate matter)	2 mg/m³	ACGIH
		TWA (Respirable)	5 mg/m³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m³	OSHA Z-1
Titanium dioxide	13463-67-7	TWA (Respirable particulate matter)	2.5 mg/m³ (Titanium dioxide)	ACGIH
		TWA (total dust)	15 mg/m³	OSHA Z-1

This substance(s) is not bioavailable and therefore does not contribute to a dust inhalation hazard.

Titanium dioxide

Engineering measures : Use feasible engineering controls to minimize exposure to

compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and

use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any

hazardous chemical is limited. Use a positive pressure air

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version **Revision Date:** SDS Number: Date of last issue: 09/30/2023 Date of first issue: 11/07/2014 11.2 09/28/2024 29118-00025

supplied respirator if there is any potential for uncontrolled

release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material Chemical-resistant gloves

Eye protection Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Work uniform or laboratory coat. Hygiene measures

If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance powder

Color blue green

Odor No data available

Odor Threshold No data available

pΗ No data available

No data available Melting point/freezing point

Initial boiling point and boiling

range

No data available

Flash point Not applicable

Not applicable Evaporation rate

Flammability (solid, gas) May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) No data available

Upper explosion limit / Upper

flammability limit

No data available

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

Lower explosion limit / Lower :

flammability limit

No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials

Hazardous decomposition

products

: No hazardous decomposition products are known.

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,588 mg/kg

Method: Calculation method

Components:

metformin hydrochloride:

Acute oral toxicity : LD50 (Rat): 1,000 mg/kg

LD50 (Mouse): 1,450 - 3,500 mg/kg

LD50 (Monkey): 463 mg/kg

LD50 (Rabbit): 350 mg/kg

LD50 (Guinea pig): 500 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Sitagliptin:

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg

LD50 (Mouse): 3,000 mg/kg

Kaolin:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg

Titanium dioxide:

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Assessment: The substance or mixture has no acute inhala-

tion toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

metformin hydrochloride:

Species : Rabbit

Result : Mild skin irritation

Sitagliptin:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Kaolin:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Titanium dioxide:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

metformin hydrochloride:

Species : Rabbit

Result : Mild eye irritation

Sitagliptin:

Species : Rabbit

Result : Irritating to eyes. Method : Draize Test

Kaolin:

Species : Rabbit

Result : No eye irritation

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

Titanium dioxide:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Sitagliptin:

Test Type : Local lymph node assay (LLNA)

Species : Mouse

Method : OECD Test Guideline 429
Result : Not a skin sensitizer.

Titanium dioxide:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Skin contact
Species : Mouse
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

metformin hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: in vitro test

Test system: mouse lymphoma cells

Result: negative

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Cellulose:

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Sitagliptin:

Genotoxicity in vitro : Test Type: Ames test

Result: negative

Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro) Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse Result: negative

Carcinogenicity

Not classified based on available information.

Components:

metformin hydrochloride:

Species : Mouse Exposure time : 91 weeks

Dose : 1500 mg/kg body weight

Result : negative

Species : Rat, male Application Route : Oral

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

Exposure time : 104 weeks

Dose : 900 mg/kg body weight

Result : negative

Species : Rat, female

Application Route : Oral Exposure time : 104 weeks

LOAEL : 900 mg/kg body weight

Result : negative

Target Organs : Uterus (including cervix)

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Sitagliptin:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Rat

Application Route : oral (drinking water)

Exposure time : 2 Years
Result : positive
Target Organs : Liver

Remarks : Significant toxicity observed in testing

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

Titanium dioxide:

Species : Rat

Application Route : inhalation (dust/mist/fume)

Exposure time : 2 Years

Method : OECD Test Guideline 453

Result : positive

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

This substance(s) is not bioavailable and therefore does not

contribute to a dust inhalation hazard.

Carcinogenicity - Assess-

ment

Limited evidence of carcinogenicity in inhalation studies with

animals.

IARC Group 2B: Possibly carcinogenic to humans

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

Titanium dioxide 13463-67-7

OSHANo component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

metformin hydrochloride:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 600 mg/kg body weight

Result: No effects on fertility.

Effects on fetal development : Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 600 mg/kg body weight

Result: No teratogenic effects.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Embryo-fetal toxicity.: NOAEL: 140 mg/kg body weight

Result: No teratogenic effects.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Sitagliptin:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL Parent: 1,000 mg/kg body weight Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 09/28/2024 29118-00025 11.2 Date of first issue: 11/07/2014

Species: Rat

Application Route: Oral

Teratogenicity: LOAEL: 250 mg/kg body weight Result: Embryotoxic effects and adverse effects on the

offspring were detected., No teratogenic effects.

Test Type: Embryo-fetal development

Species: Rabbit

Teratogenicity: NOAEL: 125 mg/kg body weight

Result: No teratogenic effects.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

metformin hydrochloride:

Species Rat

NOAEL 125 mg/kg Application Route Oral Exposure time 1 year

Remarks No significant adverse effects were reported

Species Rabbit NOAEL 100 mg/kg Application Route Oral Exposure time

Remarks No significant adverse effects were reported

Species Dog **NOAEL** 50 mg/kg Subcutaneous Application Route

Exposure time 2 year

Remarks No significant adverse effects were reported

Cellulose:

Species Rat

NOAEL >= 9,000 mg/kgIngestion Application Route Exposure time 90 Days

Sitagliptin:

Species Mouse NOAEL 500 mg/kg LOAEL 1,000 mg/kg

Application Route Oral

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

Exposure time : > 2 y
Target Organs : Kidney

Species : Rat

NOAEL : 500 mg/kg LOAEL : 1,000 mg/kg

Application Route : Oral Exposure time : 14 Weeks

Target Organs : Liver, Kidney, Heart, Teeth

Species : Dog
NOAEL : 10 mg/kg
LOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks

Target Organs : Central nervous system

Symptoms : Loss of balance

Remarks : The mechanism or mode of action may not be relevant in

humans.

Species : Dog
NOAEL : 2 mg/kg
LOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 27 Weeks

Target Organs : Skeletal muscle, Central nervous system

Symptoms : Loss of balance

Remarks : The mechanism or mode of action may not be relevant in

humans.

Species : Monkey
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Remarks : No significant adverse effects were reported

Titanium dioxide:

Species : Rat

NOAEL : 24,000 mg/kg Application Route : Ingestion Exposure time : 28 Days

Species : Rat NOAEL : 10 mg/m³

Application Route : inhalation (dust/mist/fume)

Exposure time : 2 y

Aspiration toxicity

Not classified based on available information.

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

Experience with human exposure

Components:

metformin hydrochloride:

Skin contact : Remarks: May irritate skin. Eye contact : Remarks: May irritate eyes.

Ingestion : Symptoms: Diarrhea, Nausea, Vomiting, Gastrointestinal dis-

comfort, flatulence, asthenia, Fatigue, Headache

Sitagliptin:

Inhalation : Symptoms: upper respiratory tract infection, pharyngitis,

Headache

Ingestion : Symptoms: upper respiratory tract infection, nasopharyngitis,

Headache, Nausea, Abdominal pain, Diarrhea

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

metformin hydrochloride:

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 10 mg/l

Exposure time: 33 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 40 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

Sitagliptin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 60 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 39

mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2

mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l

Exposure time: 33 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 9.8 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 150 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 150 mg/l Exposure time: 3 h

Test Type: Respiration inhibition

Titanium dioxide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l

Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 09/28/2024 11.2 29118-00025 Date of first issue: 11/07/2014

Persistence and degradability

Components:

metformin hydrochloride:

Result: rapidly degradable Biodegradability

Biodegradation: 50 % Exposure time: 2 hrs

Cellulose:

Biodegradability Result: Readily biodegradable.

Sitagliptin:

Biodegradability Result: not rapidly degradable

Biodegradation: 39.7 % Exposure time: 28 d

Method: OECD Test Guideline 314

Hydrolysis: 50 %(401 d) Stability in water

Method: OECD Test Guideline 111

Bioaccumulative potential

Components:

metformin hydrochloride:

Partition coefficient: n-

octanol/water

log Pow: -2

Sitagliptin:

Partition coefficient: n-

octanol/water

log Pow: -0.03

Mobility in soil

Components:

metformin hydrochloride:

Distribution among environlog Koc: 4.3

Method: OECD Test Guideline 106 mental compartments

Sitagliptin:

Distribution among environ-

mental compartments

log Koc: 4.37

Other adverse effects

No data available

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust

Acute toxicity (any route of exposure)

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

US State Regulations

Pennsylvania Right To Know

metformin hydrochloride 1115-70-4
Hydroxypropyl methylcellulose 9004-65-3
Cellulose 9004-34-6
Sitagliptin 654671-77-9
Polyvinyl pyrrolidone 9003-39-8
Kaolin 1332-58-7

California Prop. 65

WARNING: This product can expose you to chemicals including Titanium dioxide, which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

California List of Hazardous Substances

Polyvinyl pyrrolidone 9003-39-8

California Permissible Exposure Limits for Chemical Contaminants

 Cellulose
 9004-34-6

 Kaolin
 1332-58-7

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

NFPA 704:

Health Instability

Special hazard

HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CAL PEL : California permissible exposure limits for chemical contami-

nants (Title 8, Article 107)

NIOSH REL : USA. NIOSH Recommended Exposure Limits

OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim-

its for Air Contaminants

OSHA Z-3 : USA. Occupational Exposure Limits (OSHA) - Table Z-3 Min-

eral Dusts

ACGIH / TWA : 8-hour, time-weighted average CAL PEL / PEL : Permissible exposure limit

NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour

workday during a 40-hour workweek

OSHA Z-1 / TWA : 8-hour time weighted average OSHA Z-3 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to

according to the OSHA Hazard Communication Standard



Sitagliptin / Metformin Extended Release Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11.2 09/28/2024 29118-00025 Date of first issue: 11/07/2014

50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development: OPPTS - Office of Chemical Safety and Pollution Prevention: PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship: RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to

compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/28/2024

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8